Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2014)
21 slides from Cyclopharm's shareholder meeting presentation, May 22, 2014
Slide 1: Cyclopharm Limited Annual General Meeting
Nuclear Medicine Cyclopharm Limited Annual General Meeting 22 May 2014
Slide 2: For personal use only
For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm
Slide 3: For personal use only
For personal use only Chairman’s Address Managing Director’s Review Question Time Business Close 3
Slide 4: Chairman's Address
Chairman’s Acdldress Vanda Gould
Slide 5: Cyclopharm - helping save lives everyday!
For personal use only Cyclopharm - helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to PET central pharmacies to Developing centres that provide generate revenue, profits and strong produce radiopharmaceuticals services ranging from special
Slide 6: Managing Director's Review
Managing Directors Review James McBrayer
Slide 7: Opportunities and Challenges
For personal use only Opportunities and Challenges Technegas business strong and growing with Patient Administration Sets (PAS) units increasing 7% over previous year United States FDA Clinical trial commences Q4 2012 Cyclotron facility completed its third year of operations with sales volume
Slide 8: For personal use only
For personal use only 8
Slide 9: Solid growth in revenue and cash flow
For personal use only Solid growth in revenue and cash flow 2013 2012 • TG revenue 12% above prior Technegas Division year with PAS volumes 7% Sales Revenue $10,456,919 $9,367,984 higher Profit Before Tax and Finance Costs $2,025,694 $1,124,977 • $2,429k Loss from MUH Molecular Imaging Sales Revenue
Slide 10: Low Debt
For personal use only Low Debt Year end 31 December 2013 2012 Current Assets $7,451,504 $9,032,983 • Decrease in Non- Non-current Assets $4,447,663 $12,623,380 current Assets from Total Assets $11,899,167 $21,656,363 $8.86m impairment charge to Molecular Current Liabilities $5,210,491 $5,928,044 Ima
Slide 11: For personal use only
For personal use only 11
Slide 12: Technegas sold across the world; revenue by region
For personal use only • Technegas is sold in 55 countries across the world • Over 3,000,000 patient studies since 1986 • 1,300 Technegas generators sold globally • Expanding operations in North America pending clinical trial and approval of United States FDA North Asia America Pacific 17% 22% • Targ
Slide 13: Technegas sales of PAS continue to rise
For personal use only Technegas sales of PAS continue to rise Technegas Revenue in $m Patient Administration Sets (PAS) 8.58 7.27 • PAS revenue up 18% from 2012 • PAS volumes up 7% from 2012 1.22 0.83 2012 2013 Technegas Generators PAS Technegas Generators Technegas Volume in Units • TG Generator re
Slide 14: Revenue impacted by ANSTO-PetNet matter
For personal use only Revenue impacted by ANSTO-PetNet matter • Third full year of operations recording revenue at $1,425k equating to 4% growth • Strong competition from public sector cyclotron facilities in NSW • Board decision to close commercial operations in April 2014 • Claim against ANSTO sch
Slide 15: Molecular Imaging joint venture
For personal use only PET • Joint venture with: X-Ray • 50% Alfred Health Solutions • 30% Macquarie University CT • 20% CycloPet • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform MRI • Macquarie University Hospital start-up slower than expected Ultra- sound
Slide 16: Ultralute
For personal use only • Cyclopharm patented technology • Extends the effective life of Mo-99 generator up to 50% • Improves utilisation of Tc-99m • Regulatory approval process underway • Global interest continues to grow • Further announcements regarding commercialisation due later this year 16
Slide 17: For personal use only
For personal use only 17
Slide 18: Simpler business to deliver strong earnings growth
For personal use only Simpler business to deliver strong earnings growth Technegas revenue growth driven by: - Improved demand in Europe and China - Increased sales of lower margin Technegas generators Continue USFDA trial targeting completion early 2016 with commercialisation in mid 2016 Deve
Slide 19: For personal use only
For personal use only 19
Slide 20: Question Time & Business
Question Time & Business
Slide 21: Resolution voting results
For personal use only Resolution Business For* Against Abstain Proxy’s discretion 1 Remuneration Report 24,336,652 29,762 5,000 - 2 Re-election of Mr Gould 24,344,609 19,260 7,545 - 3 Election of Mr Townsing 24,354,102 16,800 512 - 4 Renewal of share buy- 24,354,614 - 16,800 - back capacity *Include